$INBS News

Intelligent Bio Solutions Initiates Multi-Site Method Comparison Study To Support FDA 510(k) Submission For US Market Clearance Of Intelligent Fingerprinting Drug Screening System For Opiate Codeine

Intelligent Bio Solutions Q3 EPS $(1.80) Up From $(4.40) YoY, Sales $1.060M Up From $728.867K YoY

Intelligent Bio Solutions Initiates Validation Study for Rapid Drug Screening Cartridge Targeting 70% Faster Results

Intelligent Bio Solution Launches Validation Study Targeting A Significant Reduction In The Time Required To Analyze Its Intelligent Fingerprinting Drug Screening System

Intelligent Bio Solutions Advances Upcoming FDA 510(k) Submission, Successfully Completes Penetration Testing with No Major Vulnerabilities Identified

Intelligent Bio Solutions Completes Penetration Testing As Part Of Its Upcoming FDA Submission

Intelligent Bio Solutions shares are trading lower. The company said it completed initial clinical Cut-off Study supporting its FDA 510(k) submission for U.S. market clearance of its Intelligent Fingerprinting Drug Screening System for detection of the opiate codeine.

Intelligent Bio Solutions shares are trading lower. The company said it completed initial clinical Cut-off Study supporting its FDA 510(k) submission for U.S. market clearance of its Intelligent Fingerprinting Drug Screening System for detection of the opiate codeine.

Intelligent Bio Solutions Completes Clinical Cut-off Study, Advances FDA 510(k) Clinical Program Targeting Multi-Billion-Dollar U.S. Drug Screening Market

Intelligent Bio Solutions Completes Its Initial Clinical Cut-Off Trial For FDA 510(k) Submission For U.S. Market Clearance Of Its Intelligent Fingerprinting Drug Screening System

Intelligent Bio Solutions Strengthens European IP Portfolio with Eighth Patent Grant

Intelligent Bio Solutions Adds Eighth European Patent To Portfolio, Secures Patent For Fingerprint Chemical Analysis With Fingerprint Deposition Volume

Intelligent Bio Solutions Successfully Manufactures and Ships First Readers with New Partner, Accelerating Scale and Driving Gross Margin Expansion in Anticipation of Planned U.S. Entry

Intelligent Bio Solutions Partners with Bouygues UK, Part of Multi-Billion Dollar Global Construction Giant Bouygues Construction, for UK Drug Testing Rollout

Intelligent Bio Solutions Partners With Bouygues UK For Deployment Of INBS's Fingerprint Drug Screening Technology Across Its UK Operations

Intelligent Bio Solutions Reports Record Fiscal Second Quarter Revenue Growth of 48% with Reader Sales Surging 104% Year-Over-Year

Intelligent Bio Solutions Q2 EPS $(2.82) Up From $(4.96) YoY, Sales $896.774K Up From $607.494K YoY

Intelligent Bio Solutions Expects to Report Fiscal Second Quarter 2026 Revenue Growth of Approximately 48% Year-Over-Year, Surpassing $2 Million in Total Revenue for First Half of Fiscal Year

Intelligent Bio Solutions Initiates Additional Clinical Studies for FDA 510(k) Submission Supporting Planned Entry into Multi-Billion Dollar U.S. Market

Intelligent Bio Solutions Commences Clinical Studies To Support FDA 510(k) Submission For U.S. Market Clearance Of Intelligent Fingerprinting Drug Screening System